The most common AE of neratinib was gastrointestinal toxicity such as diarrhea; in patients with BC, the response rate of neratinib was ≥ 32%, and was higher when used together with other anti-HER2 agents (e.g., 63% when with T-DM1). The gene discussed is ERBB2; the disease is breast cancer.